

Take a deeper look.

**SANOFI GENZYME IS DEDICATED TO ONCOLOGY RESEARCH
THAT CAN HELP IMPROVE PATIENT OUTCOMES.**

References: 1. Canadian Cancer Society. Non-melanoma skin cancer statistics. Available at: <http://www.cancer.ca/en/cancer-information/cancer-type/skin-non-melanoma/statistics/?region=on> 2. Public Health Agency of Canada. Non-melanoma skin cancer. Available at: <https://www.canada.ca/en/public-health/services/chronic-diseases/cancer/non-melanoma-skin-cancer.html> 3. Guenther LC *et al.* *J Cutan Med Surg* 2015;19(3):205-15. 4. Chalmers ZR *et al.* *Genome Med* 2017;9(1):34. 5. Sapijaszko M *et al.* *J Cutan Med Surg* 2015;19(3):249-59.

When treating advanced cutaneous SCC,

ARE WE LOOKING AT THE WHOLE PROBLEM?



NMSC (NON-MELANOMA SKIN CANCER)

Most common cancer diagnosed in Canadians ¹	76,100 Canadians diagnosed with it in 2014 and 440 died from it the same year ²	Causes significant disfigurements ³	Poor prognosis for metastatic NMSC with a 5-year survival of 44% ³
--	--	--	---

BASAL CELL CARCINOMA (BCC)²


- 77% of all NMSC
- 1 in 8 Canadians will develop BCC in their lifetime

SQUAMOUS CELL CARCINOMA (SCC)^{2,4}

- 23% of all NMSC
- 1 in 20 Canadians will develop SCC in their lifetime
- High tumor mutational burden (TMB)

SCC HAS A HIGHER RATE OF METASTASIS THAN BCC²
METASTATIC SCC IS ASSOCIATED WITH A 5-YEAR SURVIVAL OF 34.4%⁵

For patients with high-risk cutaneous SCC – explore your options



Adapted from the Canadian Non-Melanoma Skin Cancer Guidelines⁵

MMS: Mohs micrographic surgery